Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
Patients included in the study will receive induction treatment during 6 months, followed by
receive high-dose therapy followed by peripheral blood stem cell transplantation.
Approximately 3 months after peripheral blood stem cell transplantation patients will receive
consolidation treatment during 2 months.
Subsequently patients will start maintenance treatment during 24 months. Therefore, the total
duration of the treatment will be approximately 36 months.